UPLOAD Filing
Dogwood Therapeutics, Inc.
Date: Jan. 27, 2026 · CIK: 0001818844 · Accession: 0000000000-26-000860
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-292750
Letter
January 21, 2026 Greg Duncan Chairman and Chief Executive Officer Dogwood Therapeutics, Inc. 44 Milton Avenue Alpharetta, GA 30009 Re:Dogwood Therapeutics, Inc. Registration Statement on Form S-3 Filed January 15, 2026 File No. 333-292750 Dear Greg Duncan: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Daniel Crawford at 202-551-7767 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc:Darrick M. Mix, Esq.
Show Raw Text
January 21, 2026
Greg Duncan
Chairman and Chief Executive Officer
Dogwood Therapeutics, Inc.
44 Milton Avenue
Alpharetta, GA 30009
Re:Dogwood Therapeutics, Inc.
Registration Statement on Form S-3
Filed January 15, 2026
File No. 333-292750
Dear Greg Duncan:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Daniel Crawford at 202-551-7767 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:Darrick M. Mix, Esq.